Tashkent, Uzbekistan, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), completed its first stop in Kazakhstan from 1 to 3 June and are now visiting Tashkent, the capital of Uzbekistan, for the final leg of its Central Asia tour from 4 to 5 June. During the visit, the delegation met with senior representatives of the local government and business communities, successfully advancing collaboration opportunities across multiple sectors.The HKTDC will follow up on key projects facilitated during the visit by providing professional post-‘mission business matching and support services, with a view to expediting project implementation while continuing to assist Hong Kong enterprises in exploring further international cooperation opportunities.The business delegation facilitated the signing of 66 memoranda of understanding (MoUs) and agreements during its visit to Kazakhstan and Uzbekistan, covering areas such as trade, investment, finance, technology and aviation. In addition, 15 cooperation agreements were signed at the government level, while non-delegation members signed 15 MoUs in areas including academia and culture, bringing the total number of agreements and MoUs signed to 96. These outcomes have laid a solid foundation for deepening economic and trade ties among Hong Kong, the Chinese Mainland, Kazakhstan and Uzbekistan, underscoring Hong Kong’s role as a key platform for Mainland enterprises to go global and further promoting long-term collaboration with Central Asian markets. Looking ahead, the parties look forward to welcoming more Central Asian enterprises to Hong Kong and HKTDC’s flagship international conferences and exhibitions, including the Belt and Road Summit and InnoEX, to capitalise on Hong Kong’s strengths as an international business and trading hub and further deepen cooperation.During its stay in Uzbekistan, the delegation met with senior officials, trade bodies and business representatives, including the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan and Uzbekistan Chamber of Commerce, and IT Park Uzbekistan, to gain in-depth insights into the country’s economic developments, market environment and investment opportunities.Summing up the Central Asia visit, Mr Lee said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Mr Lee held meetings with the Presidents, Prime Ministers and other senior officials of the two countries. Both sides agreed to strengthen high-level communication and pursue multi-faceted collaboration. The Government of Uzbekistan has agreed to establish a Consulate General in Hong Kong. In addition, multiple agreements were signed, including projects with substantial investment value.Both sides recognised that the hub-to-hub cooperation model will create broader and deeper collaboration between the two regions and drive high-quality development. They will increase high-level mutual visits, support each other’s promotional activities and jointly expand their networks.”To deepen economic and trade cooperation, the HKSAR Government and the HKTDC jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officials. Prof Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”The delegation comprised business leaders from Hong Kong and 17 provinces and municipalities across the Chinese Mainland, spanning a broad range of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries as well as the media. For the first time, representatives from journalism associations joined the delegation, in response to the Policy Address’s initiative to assist the local media in expanding their network beyond Hong Kong and telling the good stories of Hong Kong. During its Kazakhstan visit, the delegation facilitated 43 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority Hong Kong and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte China and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLP29.Goldford Group and Gas Energy Solution LLP30.Hong Kong News Executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC31.Jardine Matheson and KIDF32.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan33.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology34.PCCW Limited and Kazakhtelecom35.PCCW Limited and Khabar Agency JSC36.SCMP and Astana International Financial Centre (AIFC)37.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub38.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan39.Standard Chartered Bank and Development Bank of Kazakhstan40.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.41.Templewater Limited and Freedom Holdings42.The Standard and Freedom Horizons43.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC During its Uzbekistan visit, the delegation facilitated 23 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and Chamber of Commerce and Industry of Uzbekistan (CCIU)2.Hong Kong Trade Development Council (HKTDC) and IT Park Uzbekistan3.Airport Authority Hong Kong and Fly Khiva Group4.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and SINOCHEM PLASTICS GROUP “MCHJ XK”5.Belt and Road General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)6.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP7.Chinese Manufacturers' Association of Hong Kong and Chamber of Commerce and Industry of Uzbekistan (CCIU)8.Federation of Hong Kong Industries (FHKI) and Tashkent City Municipality9.Cyberport and IT Park Uzbekistan10.The Hong Kong General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)11.Law Society of Hong Kong and Chamber of Advocates of the Republic of Uzbekistan12.A-Grade Energy Ltd and Zarafshan Golden Group of Uzbekistan13.China International Capital Corporation Limited and National Bank of Uzbekistan14.China International Capital Corporation Limited and Tashkent City Municipality of the Republic of Uzbekistan15.Deloitte China and Orient Group and CITIC16.Goldford Group and Automated Solutions Center17.Templewater Limited and Uzbek-Oman Investment Company LLC18.Templewater Limited and CSCEC INTERNATIONAL MCHJXK (China State Construction International Holdings Limited)19.Templewater Limited and Tashkent City Municipality of the Republic of Uzbekistan20.The Standard and Tashkent City Municipality of the Republic of Uzbekistan21.Changchun GeneScience Pharmaceutical Co., Ltd. with Vita Group Farm22.Guangzhou Pharmaceutical Holdings Limited and ADN Pharm-Sanoat Uzbekistan23.Shaanxi Tirain Science & Technology Co., Ltd. and Geodesy, Cartography and Remote Sensing Department, Cadastral Agency under the State Tax Committee of the Republic of UzbekistanOther non-delegate organisations have also taken this opportunity to establish collaborations in various fields, including education, culture, and more:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan5.City University of Hong Kong and Satbayev University6.City University of Hong Kong and Tashkent State Technical University7.Education University of Hong Kong and Nazarbayev University8.HKT and Education University of Hong Kong9.Hong Kong Polytechnic University and Nazarbayev University10.Hong Kong Polytechnic University and El-Yurt Umidi Foundation11.Hong Kong Polytechnic University and New Uzbekistan University (NUU)12.Thei and BILIM-INNOVATION International Social Foundation13.Thei and L.N. Gumilyov Eurasian National University14.CCBI and Uzbekistan BA Association15.West Kowloon Cultural District Authority – Hong Kong Palace Museum and State Museum of History of UzbekistanPhoto download: https://bit.ly/4fmUpRLSumming up the Central Asia visit, John Lee, Chief Executive of the HKSAR, said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Prof Frederick Ma, Chairman of the HKTDC, joined John Lee, Chief Executive of the HKSAR, senior officials of the HKSAR Government and members of the delegation in meeting the media, noting that the Central Asia visit led by the Chief Executive has successfully opened doors to business cooperation with Central AsiaThe HKSAR Government and the Hong Kong Trade Development Council (HKTDC) jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officialsProf Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”During its visit to Uzbekistan, the delegation facilitated 23 memoranda of understanding (MoUs) and agreementsThe delegation met with representatives of the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan to gain in-depth insights into bilateral trade and investment opportunities. During the meeting, Prof Frederick Ma, Chairman of the HKTDC, met with Khodjayev Jamshid Abdukhakimovich, Deputy Prime Minister of the Republic of UzbekistanThe delegation met with representatives of the Uzbekistan Chamber of Commerce to gain in-depth insights into the country’s economic developments, market environment and investment opportunitiesThe delegation visited IT Park Uzbekistan to learn about the latest developments in innovation and technologyMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation marks an important milestone in the Group’s strategy to diversify its manufacturing footprint beyond the Chinese Mainland while deepening its production presence in Southeast Asia.The Penang facility spans approximately 60,000 square feet and houses 12 production lines, providing a monthly production capacity of 250,000 to 300,000 units. It operates as an OEM manufacturing base for industrial electronics, environmental control and electronics power modules, serving international customers. The additional capacity broadens the Group’s manufacturing scale, reflects growing customer demand and creates a platform for further business development.The opening builds on the Group’s strategic initiatives completed in 2025, including the acquisition of manufacturing operations in Penang, Malaysia, and Ho Chi Minh City, Vietnam. The move into Malaysia represented the Group’s first production foothold outside the Chinese Mainland. Following the acquisition in August 2025, the Group has expanded and upgraded the Penang facility with advanced equipment and process improvements to strengthen efficiency and quality control. It now manufactures irrigation sensors, thermostats, security devices and lithium battery packs.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “The Penang facility plays an important role in advancing the Group’s strategy to build a more diversified manufacturing network. Together with our expansion into Vietnam, we are reinforcing our production capabilities and increasing supply chain flexibility across our operations. These initiatives strengthen the Group’s resilience and agility in supporting our customers in an increasingly dynamic global environment.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “The Penang operation is ramping up steadily and is already supporting a growing pipeline of orders from existing and new customers. With expanded production lines and upgraded systems, we are ready to scale output as demand increases. The Group is evaluating the potential establishment of another facility in Malaysia with comparable capacity to support the Group’s next phase of growth.” Official representatives of Malaysia, together with Alltronics’ Board of Directors and management, officiate at the ribbon-cutting ceremony for the Group’s new Malaysia facility. With 12 production lines and a monthly capacity of 250,000 to 300,000 units, Alltronics’ Malaysia facility broadens the Group’s manufacturing scale and supports growing customer demand.About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GLASGOW / HONG KONG - Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m². Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics"This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases," said Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics. "We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide."About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. For more information, please visit www.hightidetx.com Contact: pr@hightidetx.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 5, 2026 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) celebrated its 11th anniversary by hosting the annual Charity Golf & Gala Dinner at Sentosa Golf Club on 28 May 2026.The event, graced by Guest of Honour Mr Masagos Zulkifli, Minister for Social and Family Development, drew over 120 golfers from Singapore’s legal and professional community for a day of sports and philanthropy, culminating in a gala dinner that reaffirmed the Foundation’s enduring commitment to make a difference in the lives of those it serves. The event also marked the 15th anniversary of RHTLaw Asia LLP.The Foundation raised more than S$280,000 through the event to benefit four local charities, namely PCF Sparkle Care, Singapore Road Safety Council, Singapore Golf Association, and Bethel Community Services.In addition to the fundraising milestone, the evening saw a leadership transition within the Foundation. Ms Kaylee Kwok stepped down as Chairman with effect from 28 May 2026, having stewarded the Foundation through 4 years of sustained growth and deepening community impact.“It has been a great privilege to serve as Chairman of ONERHT Foundation. What began as a conviction that the legal and professional community could do more has grown into something truly meaningful, with over S$6 million raised, more than 40 beneficiaries supported, and countless lives touched across Singapore and the region. I am deeply grateful to our sponsors, donors, partners and our ONERHT colleagues for their strong support and commitment. I leave with full confidence that the Foundation’s best years are still ahead,” said Ms Kaylee Kwok.Mr Nandakumar Renganathan has been appointed as the new Chairman of ONERHT Foundation, also with effect from 28 May 2026. Mr Nandakumar brings with him a deep commitment to the Foundation’s mission and vision to extend its reach across Singapore and the broader ASEAN region.“I am deeply honoured to take on this role and equally grateful to Kaylee for her leadership and contributions to the Foundation. ONERHT Foundation stands for something bigger than any one of us, a belief that those of us in the legal and professional community have a responsibility to give back, not just once, but consistently and with purpose. I look forward to working with our sponsors, donors, partners and beneficiaries as well as our ONERHT colleagues to carry that mission forward and extend our reach even further across Singapore and ASEAN,” said Mr Nandakumar.The evening also witnessed the signing of a Memorandum of Understanding (MOU) between RHTLaw Asia and the Association for Persons with Special Needs (APSN), marking a new chapter in the Foundation’s commitment to building meaningful and lasting partnerships with the communities it serves. ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$6 million to support more than 40 beneficiaries involved in education, environmental protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationFor media enquiries, please contact:Melody OngEmail: melody@waterbrooks.com.sg+65 8901 9780General enquiries:Email: query@waterbrooks.com.sg+65 9338 8166 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com